Skip to main content

Table 5 New manufacturing method: improved product purity

From: Bone marrow-derived cells for cardiovascular cell therapy: an optimized GMP method based on low-density gradient improves cell purity and function

  % Lymphocytes % Monocytes % MNC % Granulocytes PLT/WBC
Current Method (n = 43)a 48 ± 13 (21-71) 9 ± 3 (5-15) 57 ± 15 (26-84) 43 ± 14 (16-74) 6 ± 5 (1-28)
New Method (n = 24)b 52 ± 11 (34-69) 15 ± 4 ** (8-22) 66 ± 11** (42-85) 34 ± 11** (15-58) 5 ± 2 (2-10)
  1. Data are reported as mean + standard deviation (range).
  2. MNC: Mononuclear cells (lymphocytes +μmonocytes); PLT: Platelets; WBC: White Blood Cells.
  3. ailiac crest (n = 33) and sternal (n = 10) bone marrow samples; bsternal samples only; **p < 0.01 (unpaired T-test).
\